Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Benoit Tessoulin, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Cedric Rossi, Caroline Milin, Ludovic Fouillet, Charles Herbaux, Emmanuelle Tchernonog, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2024-206778

Published: 2024

Journal Articles

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Yannick Le Bris, Barbara Burroni, Marguerite Fournier, Morgane Cheminant, Sara Ek, Eva Hoster, Marie-Helene Delfau-Larue, Clémentine Sarkozy, Mary B. Callanan, Benoit Tessoulin, David Chiron, Martin Dreyling, Mats Jerkeman, Steven Le Gouill, Olivier Hermine

Blood (2024) 144 (Supplement 1): 4360.

https://doi.org/10.1182/blood-2024-199152

Published: 2024

Journal Articles

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Ophélie Champion, Sophie Maiga, Christelle Dousset, Agnès Aubry, Céline Bellanger, François Guillonneau, Jose Antonio Moreno, Ohyun Kwon, Philippe Moreau, David Chiron, Catherine Pellat-Deceunynck, Cyrille Touzeau, Patricia Gomez-Bougie

Blood (2024) 144 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2024-194462

Published: 2024

Journal Articles

Unraveling MCL biology to understand resistance and identify vulnerabilities

clémentine Sarkozy, Benoit Tessoulin, David Chiron

Blood blood.2023022351.

https://doi.org/10.1182/blood.2023022351

Published: 2024

Journal Articles

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

Blood (2024) 143 (13): 1242–1258.

https://doi.org/10.1182/blood.2023021581

Published: 2024

Includes: Supplemental data

Journal Articles

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

Blood (2023) 142 (18): 1543–1555.

https://doi.org/10.1182/blood.2023020211

Published: 2023

Includes: Supplemental data

Journal Articles

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

Romane Durand, Domitille Costes-Tertrais, Geraldine Descamps, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Elise Douillard, Jennifer Derrien, Celine Bellanger, David Chiron, Stephane Minvielle, Cyrille Touzeau, Philippe Moreau, Martine Amiot, Patricia Gomez-Bougie, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 4198–4199.

https://doi.org/10.1182/blood-2022-155862

Published: 2022

Journal Articles

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

David Chiron, Emmanuelle Menoret, Charlotte Kervoelen, Sophie Maïga, Celine Bellanger, Benoit Tessoulin, Cyrille Touzeau, Hélène Asnagli, Andy Parker, Philip Beer, Catherine Pellat-Deceunynck

Blood (2022) 140 (Supplement 1): 6014–6015.

https://doi.org/10.1182/blood-2022-159449

Published: 2022

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 5996–5997.

https://doi.org/10.1182/blood-2022-168617

Published: 2022

Journal Articles

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Salomé Decombis, Celine Bellanger, Yannick Le Bris, Delphine Boulet, Jane Jardine, Christelle Dousset, Audrey Ménard, Charlotte Kervoelen, Elise Douillard, Philippe Moreau, Stephane Minvielle, Agnes Moreau-Aubry, Benoit Tessoulin, Nicolas Bidère, Steven Le Gouill, Catherine Pellat-Deceunynck, David Chiron

Blood (2022) 140 (Supplement 1): 2044–2045.

https://doi.org/10.1182/blood-2022-157694

Published: 2022

Journal Articles

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Salome Decombis, Antonin Papin, Celine Bellanger, Clara Sortais, Christelle Dousset, Yannick Le Bris, Stephanie Blandin, Philippe Hulin, Benoit Tessoulin, Mathieu Rouel, Steven Le Gouill, Agnes Moreau-Aubry, Catherine Pellat-Deceunynck, David Chiron

Blood (2021) 138 (Supplement 1): 781.

https://doi.org/10.1182/blood-2021-144839

Published: 2021

Journal Articles

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal, Charles Herbaux, Benoit Tessoulin, Emmanuelle Tchernonog, Cédric Rossi, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Simon Rule

Blood (2021) 137 (7): 877–887.

https://doi.org/10.1182/blood.2020008727

Published: 2021

Includes: Supplemental data

Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 1530.

https://doi.org/10.1182/blood-2019-125681

Published: 2019

Journal Articles

Three targets in 1 shot against ibrutinib resistance

David Chiron

Blood (2019) 133 (9): 888–889.

https://doi.org/10.1182/blood-2018-12-892760

Published: 2019

Journal Articles

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Antonin Papin, Benoit Tessoulin, MD, Céline Bellanger, Anne Moreau, MD, Yannick LE Bris, MDPharmD, Herve Maisonneuve, MD, Philippe Moreau, Cyrille Touzeau, MD PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD PhD, David Chiron, PhD

Blood (2018) 132 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2018-99-114504

Published: 2018

Journal Articles

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Blood (2018) 132 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2018-99-113303

Published: 2018

Journal Articles

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Krimo Bouabdallah, MD, Guillaume Cartron, Rene-Olivier Casasnovas, MD, Noel-Jean Milpied, MD, Thomas Gastinne, MD, Andrew John Davies, PhD, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule, MD

Blood (2018) 132 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2018-99-113777

Published: 2018

Journal Articles

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Yannick LE Bris, MDPharmD, Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Benoit Tessoulin, MD, Florence Magrangeas, PhD, Marie-Helene Delfau, MD, Catherine Thieblemont, MD, Lucie Oberic, MD, Krimo Bouabdallah, MD, Emmanuel Gyan, MD PhD, David Chiron, PhD, Catherine Pellat-deceunynck, PhD, Mary Callanan, PhD, Stephane Minvielle, PhD, Marie C Bene, PharmSci, PhD, Olivier Hermine, MD PhD, Steven Le Gouill, MD PhD

Blood (2018) 132 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2018-99-113268

Published: 2018

Journal Articles

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

David Chiron, Céline Bellanger, Antonin Papin, Benoit Tessoulin, Christelle Dousset, Sophie Maiga, Anne Moreau, Julie Esbelin, Valérie Trichet, Selina Chen-Kiang, Philippe Moreau, Cyrille Touzeau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2016) 128 (24): 2808–2818.

https://doi.org/10.1182/blood-2016-06-720490

Published: 2016

Includes: Supplemental data

Journal Articles

High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group

Yannick Le Bris, PharmD, Florence Magrangeas, Olivier Hermine, MD PhD, David Chiron, PhD, Danielle Canioni, Anne Moreau, MD, Marie C Bene, PharmSciD, PhD, Loic Campion, Stephane Minvielle, Steven Le Gouill, MD PhD

Blood (2016) 128 (22): 1745.

https://doi.org/10.1182/blood.V128.22.1745.1745

Published: 2016

NARROW

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Unraveling MCL biology to understand resistance and identify vulnerabilities

A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma

TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1

STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

The IL32/BAFF Axis Supports Prosurvival Dialog in the Lymphoma Ecosystem and Is Disrupted By NIK Inhibition

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Three targets in 1 shot against ibrutinib resistance

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy — a Study By the Lysa Group

Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial

Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group

Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma

High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only